Antibodies

21 Sep 2008 Findings from Landmark Study show Ustekinumab Demonstrated Superior Efficacy to Enbrel(R) (Etanercept) in Treatment of Moderate to Severe Plaque Psoriasis
17 Sep 2008 Bio3 Research S.r.l. and ProtElix Inc. enter into an agreement for the development of mimic-antibody HMGB1 antagonists to prevent restenosis and atherosclerotic plaque progression
17 Sep 2008 InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies
16 Sep 2008 Denosumab Osteoporosis Trial Finds Patients Transitioned from Alendronate (Fosamax(R)) to Denosumab Achieved Significantly Greater Gains in Bone Mineral Density versus Those Continuing on Alendronate
16 Sep 2008 Merck KGaA: New First-Line Data Demonstrate Response Rates of Up to 80% for Erbitux in KRAS Wild-Type Metastatic Colorectal Cancer (mCRC)
16 Sep 2008 New data confirms Avastin as the only biologic to demonstrate overall survival when used first-line in metastatic colorectal cancer patients with K-RAS (wild-type) gene status
16 Sep 2008 New Programs Added in Antibody Collaboration Between XOMA and Takeda
16 Sep 2008 ENOBIA PHARMA PRESENTS PRECLINICAL DATA SHOWING ENB-0040 SIGNIFICANTLY IMPROVED SURVIVAL AND HEALED SKELETAL MANIFESTATIONS OF SEVERE HYPOPHOSPHATASIA IN MICE
15 Sep 2008 Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
15 Sep 2008 Updated Survival Data from Three Phase 2 Ipilimumab Studies Showed Almost Half of Previously Treated Metastatic Melanoma Patients Alive Beyond One Year
15 Sep 2008 Pfizer Oncology Presents Safety and Efficacy Results Of CP-751,871 Study At ESMO 2008
14 Sep 2008 MedImmune Further Expands Autoimmune Disease Research Program Through Collaboration with SBI Biotech
11 Sep 2008 CuraGen Completes Enrollment in Phase II Trial of CR011-vcMMAE in Metastatic Melanoma
11 Sep 2008 Merck KGaA Submits New License Application for Erbitux in Firstline Non-Small Cell Lung Cancer in Europe
11 Sep 2008 Glenmark to initiate Phase I studies for GBR 500 by filing its IND application with the US-FDA
10 Sep 2008 XOMA Awarded $65 Million Biodefense Contract by NIAID to Advance Drug Candidates Against Botulism Toxins Into Clinical Trials
08 Sep 2008 XOMA 052 Clinical Results Support New Type 2 Diabetes Therapeutic Approach of Targeting Inflammatory Damage to Insulin-Producing Cells
08 Sep 2008 ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications
08 Sep 2008 Progenics Initiates Phase 1 Clinical Study of Targeted Therapy for Prostate Cancer
08 Sep 2008 FivePrime Initiates Phase I Clinical Trial of FP-1039 in Patients With Advanced Cancers
07 Sep 2008 Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI(R) in Oncology
04 Sep 2008 Merck Serono and Ablynx Enter Into an Agreement to Co-Discover and Co-Develop Nanobodies(R)
04 Sep 2008 FDA: Manufacturers of TNF-Blocker Drugs Must Highlight Risk of Fungal Infections
03 Sep 2008 Regeneron's ARCALYST(R) (rilonacept) Reduced Incidence of Gout Flares by 81 Percent in a Phase 2 Study in Gout Patients Initiating Urate-Lowering Therapy
03 Sep 2008 Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up
Top